Web29 mrt. 2024 · As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and … Ionis Innovation Ionis’ antisense technology With RNA as the target that forms the … Ms. Cadoret-Manier is executive vice president, chief global product strategy … Our platform technology has served as a springboard for drug discovery and … Meet Fred and Lynne. For almost 40 years, the couple did not have a name for … The Investor Relations website contains information about Ionis … From the moment of our founding, we knew that we could transform the … IONIS-MAPT Rx, also known as BIIB080, is an investigational antisense medicine … Ion-ARPA programs will be funded (up to $1M per laboratory) based on high … Web9 apr. 2024 · CARLSBAD, Calif., April 9, 2024/PRNewswire/ -- Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has …
Role of HSD17B13 in the liver physiology and pathophysiology
Web11 nov. 2024 · Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead program is focused on the highly validated, genetically-defined target, HSD17B13. There is extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with … WebALN-HSD is a subcutaneously administered, investigational RNAi therapeutic targeting HSD17B13 for the treatment of non-alcoholic steatohepatitis (NASH), in collaboration … bipy chemical
HSD17B13 - Wikipedia
Web9 apr. 2024 · AstraZeneca Licenses NASH Drug from Ionis Worth a Potential $330+ Million. Investors in Ionis Pharmaceuticals are happy this morning after the California-based … Web22 mrt. 2024 · Association of HSD17B13 rs72613567 with Aminotransferase Levels in Persons with Each PNPLA3 p.I148M Genotype. Figure 3. Web26 nov. 2024 · The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Sun DQ, et al. Nutr Metab Cardiovasc Dis, 2024 Jun 7. PMID 33853719 Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi … dallas city music hall